Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs CleanSpark Inc (CLSK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs CleanSpark Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while CleanSpark Inc trades at $12.48 (market cap $3.30B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 12.1× CleanSpark Inc's market cap, and CleanSpark Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CLSK | |
|---|---|---|
Market Cap | $39.89B | $3.30B |
Sector | Health | Technology |
52-Week High | $491.22 | $23.20 |
52-Week Low | $278.09 | $8.18 |
Enterprise Value | $38.15B | $4.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CleanSpark (CLSK) trades at $12.85, down 0.31% on the day, with a bearish technical signal. The company reported strong 2025 revenue of $766 million and net income of $364 million, but forecasts a significant net loss of -$501 million for 2026. Recent operational updates highlight bitcoin mining activities and management team expansion, while analyst consensus remains unanimously bullish with a $21.43 price target.
The stock presents a high-risk, high-reward profile. Analyst optimism contrasts with negative earnings surprises and projected profitability challenges. Key risks include execution on growth initiatives, volatile cash flows, and intense competition in the data center sector. The current price offers substantial upside to targets if the company can achieve its operational goals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About CleanSpark Inc
CleanSpark is a leading Bitcoin mining company that operates high-density data centers. It focuses on using sustainable energy to power its mining fleet and provides digital infrastructure for the blockchain ecosystem.
Read more on CLSK →
